Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib added to docetaxel + carboplatin for first-line ovarian, fallopian tube, or primary peritoneal carcinoma
NL-OMON25042Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2002
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of celecoxib, docetaxel and carboplatin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Response rate and Progression-free survival. Started Nov 2002; status: active, not recruiting.
02
Drugs
celecoxibdocetaxelcarboplatin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON25042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25042.